2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5229 EVI1/MECOM overexpression without a detectable 3q26 rearrangement is a high-risk, epigenetically activated subgroup in pediatric AML

Victor Cury, MD, André Dias Américo, MD2, Nelson Hamerschlak Sr, MD PhD3, Fabio Pires S Santos, MD, PhD4
1 Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil
2 Hospital BP, Beneficencia Portuguesa de São Paulo, São Paulo, São Paulo, Brazil
3 Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil
4 Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil

Background: Overexpression of EVI1/MECOM (3q26.2) is an adverse marker in acute myeloid leukemia (AML), classically driven by inv(3)(q21q26.2)/t(3;3)(q21;q26.2) rearrangements that hijack a distal GATA2 enhancer. High EVI1 expression also occurs without a detectable 3q26 rearrangement. The frequency, prognostic impact and mechanism of these cases are not established and have not been compared between children and adults.

Methods: We analyzed 2,609 patients from TARGET (pediatric/AYA, n=2,112), BeatAML (adult, n=346) and TCGA-LAML (adult, n=151) consortia. MECOM expression was variance-stabilized (DESeq2) and z-scored within each cohort, as the datasets differ in depth and pipeline. EVI1-high was pre-specified as the top decile, since MECOM is bimodal and near-off and a tertile cut falls inside the near-zero mode. EVI1-high cases were classified as MECOM-rearranged (canonical or other 3q26), without detectable rearrangement, or indeterminate. Overall survival (OS) was modeled separately in adults and children: adults (>=18y) by Cox adjusted for age and harmonized cytogenetic/European LeukemiaNet (ELN) risk, stratified by cohort; children by Cox adjusted for age, then also for KMT2A and NUP98 fusion status. Promoter methylation used array beta and M-values across pre-annotated MECOM CpG regions.

Results: There were 263 EVI1-high patients (10%), and of those, 221 (84%) had no detectable MECOM rearrangement, 14 (5%) had a MECOM rearrangement and 28 (11%) were classified as indeterminate. Non-rearranged cases predominated in both age groups (adults 46/51; children 175/212). In adults, EVI1-high status was not significantly associated with OS after adjustment (log-rank p=0.22) and therefore carried no prognostic value independent of ELN risk. In children, EVI1-high was associated with inferior OS (age-adjusted HR 2.25, 95% CI 1.84-2.76; p<0.0001). This association was driven by the non-rearranged subgroup (HR 2.19, 95% CI 1.78-2.70; median OS 26.4 months vs not reached), with a numerically larger estimate in the 9 rearranged cases (HR 3.91, 95% CI 1.85-8.27; median OS 9.7 months). Pediatric non-rearranged EVI1-high cases were enriched for KMT2A (56% vs 15%; odds ratio [OR] 7.4, 95% CI 4.4-12.7; p=6.2×10⁻¹³) and NUP98 fusions (19% vs 7%; OR 3.1, 95% CI 1.6-6.3), and remained adverse after adjustment for both (HR 1.65, 95% CI 1.15-2.37; p=0.007; assayed n=761). Non-rearranged cases showed EVI1 promoter-island hypomethylation vs EVI1-low cases (mean beta 0.078 [n=101] vs 0.158 [n=986]; cohort-adjusted delta-beta -0.080; p=3.6×10⁻¹¹); promoter methylation correlated inversely with expression (Spearman rho=-0.33). Adult non-rearranged EVI1-high cases were instead enriched for secondary-type and adverse lesions (TP53 18% vs 7%; ASXL1, SRSF2 and STAG2 each ~11% vs ~4%; SF3B1 7% vs 1%) and depleted of NPM1 (5% vs 34%) and DNMT3A (9% vs 24%) mutations.

Conclusions: In 2,609 patients, most cases of EVI1-high AML had no detectable 3q26 rearrangement. In children this group had inferior survival and was enriched for KMT2A and NUP98 fusions, and remained adverse after adjustment for both (HR 1.65), so EVI1 expression adds prognostic information beyond the cytogenetic and fusion workup. In adults EVI1-high expression had no independent prognostic value over conventional risk stratification systems, and adult patients were enriched for TP53 and myelodysplasia-related gene mutations. EVI1 activation was associated with EVI1 promoter hypomethylation, which was absent in rearranged cases, suggesting that cis-epigenetic derepression may be a second route to EVI1 overexpression, alongside enhancer hijacking. These data support evaluating EVI1 expression as a risk biomarker in pediatric AML.

Fabio Pires S Santos, MD, PhD: GSK - Honoraria; BeOne - Honoraria; Dr Reddy's - Honoraria; AstraZeneca - Honoraria; Bristol-Myers-Squibb - Honoraria; Novartis - Honoraria; Abbvie - Honoraria; Amgen - Honoraria; Servier - Honoraria; Pint Pharma - Honoraria; Johnson & Johnson - Honoraria; Abbvie - Research Funding; AstraZeneca - Research Funding; Johnson & Johnson - Research Funding; Servier - Research Funding